Table 1.

Summary of Patient Characteristics

Pt.	Age (yrs)	GS	Initial Rx	Years from Dx to Ra-223 Rx	Range of Ra-223 administered activity (μCi)	No. of Ra-223 doses received
1	66	9	RP+RT+AD	18	168–175	3
2	58	n/a	RP	10	119–122	2
3	65	9	RT+RT+AD	10	112	2
4	82	n/a	RP+RT+AD	23	82–84	4
5	67	n/a	n/a	n/a	108–116	4
6	72	8	RP+AD	20	103–106	6
7	66	n/a	n/a	n/a	122–133	4
8	76	7	AD	7	92	5
9	71	9	RP	9	100–106	4
10	68	n/a	RT+RT	14	132–136	6
11	78	7	RT+AD	n/a	87–91	5
12	67	10	AD	2	77	1
13	81	6	RT+AD	15	100	1
14	64	9	RT+AD	7	96–98	6
15	64	n/a	AD	9	117	2
16	57	6	RT	5	108–113	4
17	56	n/a	RP+RT+AD	5	106–113	6
18	81	n/a	n/a	6	97–100	6
19	75	n/a	AD	11	82–86	6
20	86	6	AD	9	113	1
21	88	8	RP	15	93–105	3
22	85	7	RP	11	124–125	4
23	65	n/a	n/a	n/a	140–145	2
24	70	9	AD	5	128–130	2
25	72	n/a	n/a	n/a	103–107	2

GS, primary tumor Gleason sum score; RP, radical prostatectomy; RT, radiation therapy; AD, androgen deprivation therapy; Dx, diagnosis; Rx, therapy; n/a, not available.